THROMBOGENICS NV | 22,430 Euro | +0,340 +1,54 % | |
| WKN: A0J30B ISIN: BE0003846632 Ticker-Symbol: TG4 | Frankfurt | 25.05.12 | 17:35 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 10.05. | ThromboGenics NV - Business Update | 21 | PR Newswire | |
| LEUVEN, Belgium, May 10, 2012 /PRNewswire/ --
Regulated Information
Disclosure in accordance with the law of May 2, 2007
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused... Mehr lesen zu: ThromboGenics NV - Business Update | ||||
| 17.04. | ThromboGenics Resubmits BLA for Ocriplasmin With the FDA | 64 | PR Newswire | |
| LEUVEN, Belgium, April 17, 2012 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that... Mehr lesen zu: ThromboGenics Resubmits BLA for Ocriplasmin With the FDA | ||||
| 13.04. | ThromboGenics NV: Transparency Declaration | 118 | PR Newswire | |
| LEUVEN, Belgium, April 13, 2012 /PRNewswire/ --
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it... Mehr lesen zu: ThromboGenics NV: Transparency Declaration | ||||
| 29.03. | ThromboGenics Completes Private Placement Raising €77.8 Million | 43 | PR Newswire | |
| LEUVEN, Belgium, March 29, 2012 /PRNewswire/ --
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today... Mehr lesen zu: ThromboGenics Completes Private Placement Raising €77.8 Million | ||||
| 29.03. | XFRA TG4: WIEDERAUFNAHME/RESTART | 46 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE WIRD MIT SOFORTIGER WIRKUNG WIEDER IN DEN HANDEL
AUFGENOMMEN:
THE FOLLOWING SHARE IS RESUMED TRADING WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
THROMBOGENICS... Mehr lesen zu: XFRA TG4: WIEDERAUFNAHME/RESTART | ||||
| 29.03. | XFRA TG4: AUSSETZUNG/SUSPENSION | 13 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
ThromboGenics N.V. TG4 BE0003846632 BAW/UFN Mehr lesen zu: XFRA TG4: AUSSETZUNG/SUSPENSION | ||||
| 16.03. | ThromboGenics Enters Into Commercialization Agreement for Ocriplasmin With Alcon Outside the United States | 46 | PR Newswire | |
| LEUVEN, Belgium, March 16, 2012 /PRNewswire/ --
ThromboGenics to concentrate on realizing ocriplasmin's significant commercial potential in the U.S.
ThromboGenics to receive €75 million upfront... Mehr lesen zu: ThromboGenics Enters Into Commercialization Agreement for Ocriplasmin With Alcon Outside the United States | ||||
| 08.03. | ThromboGenics Announces Business Update and 2011 Full-Year Results | 34 | PR Newswire | |
| LEUVEN, Belgium, March 8, 2012 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a business... Mehr lesen zu: ThromboGenics Announces Business Update and 2011 Full-Year Results | ||||
| 05.03. | ThromboGenics Opens New U.S. Headquarters | 52 | PR Newswire | |
| LEUVEN, Belgium, March 5, 2012 /PRNewswire/ --
U.S. Organization Continues to Build Ahead of Ocriplasmin's PlannedLaunch
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company... Mehr lesen zu: ThromboGenics Opens New U.S. Headquarters | ||||
| 24.02. | ThromboGenics to Present at the Citi 2012 Global Health Care Conference in New York | 43 | PR Newswire | |
| LEUVEN, Belgium, February 24, 2012 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that Patrik... Mehr lesen zu: ThromboGenics to Present at the Citi 2012 Global Health Care Conference in New York | ||||
| 02.02. | ThromboGenics Announces That the FDA Intends to Grant Ocriplasmin Priority Review | 43 | PR Newswire | |
| LEUVEN, Belgium, February 2, 2012 /PRNewswire/ --
Company to Re-Submit Ocriplasmin BLA to Meet Priority Review Timelines
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused... Mehr lesen zu: ThromboGenics Announces That the FDA Intends to Grant Ocriplasmin Priority Review | ||||
| 23.12. | ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA | 46 | PR Newswire | |
| LEUVEN, Belgium, December 23, 2011 /PRNewswire/ --
If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole
ThromboGenics... Mehr lesen zu: ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA | ||||
| 16.12. | ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule | 4 | Business Wire | |
| ThromboGenics NV (Euronext Brussels: THR) and co-development partner
BioInvent International (OMXS: BINV) announce today that they have
completed the enrolment of a 632-patient... Mehr lesen zu: ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule | ||||
| 16.12. | ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule | 5 | PR Newswire | |
| LEUVEN, Belgium and LUND, Sweden, December 16, 2011 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they... Mehr lesen zu: ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CELGENE CORPORATION | 55,40 | +1,24 % | Celgene Corporation to Present at Sanford C. Bernstein's 28th Annual Strategic Decisions Conference |
| MERCK KGAA | 75,00 | +0,23 % | UBS hebt Merck KGaA auf 'Buy' - Ziel 93 Euro |
| STADA ARZNEIMITTEL AG | 24,840 | -0,64 % | Kepler hebt Ziel für Stada auf 32 Euro - 'Buy' |
| GERRESHEIMER AG | 35,215 | +1,63 % | DGAP-Stimmrechte: Gerresheimer AG (deutsch) |
| CELESIO AG | 11,750 | +0,30 % | Celesio AG: Neues 13-Wochentief (11.71 Euro, Short) |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
